RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to boost remission in tough lymphoma cases
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy and a stem cell transplant can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatment. About 25 adults will receive the combination therapy. The goa…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 17, 2026 04:00 UTC
-
New drug cocktail aims to boost remission before stem cell transplant
Disease control Recruiting nowThis study tests a two-step treatment for adults with large B-cell lymphoma that came back or didn't respond to initial therapy. First, participants receive tafasitamab (an antibody) plus lenalidomide, then a chemotherapy combo (ICE) plus tafasitamab. The goal is to see if this a…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 adults will receive the combination to find the safest dose and…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug combo may bridge more patients to lifesaving CAR-T therapy
Disease control Recruiting nowThis study tests whether giving two drugs—golcadomide and rituximab—before CAR-T cell therapy can help control aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The goal is to keep the disease in check so more patients can qualify for and rec…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New Five-Drug cocktail shows promise for Hard-to-Treat lymphomas
Disease control Recruiting nowThis study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with certain aggressive lymphomas that have come back or not responded to prior therapy. The goal is to see how many patients achieve complete …
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug may boost CAR-T success in tough lymphomas
Disease control Recruiting nowThis study tests a drug called odronextamab given before CAR-T cell therapy for people with large B-cell lymphoma that has returned or not responded to treatment. The goal is to see if this approach can keep the cancer under control and help more patients successfully receive CAR…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New drug combo aims to boost stem cell transplant success in hard-to-treat lymphoma
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatment. About 43 adults will receive the combination before an autologous stem …
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 01, 2026 15:59 UTC